Additional information
Notes on contributors
Margo Michaels
All authors are affiliated with the National Cancer Institute, National Institutes of Health, in Bethesda, Md. Margo Michaels, M.P.H., is an education program specialist in the Public and Survivor Education Section, Office of Education and Special Initiatives. Andrea M. Denicoff R.N., M.S., C.A.N.P., is a clinical trials specialist in the Office of Education and Special Initiatives. Mary Anne Bright R.N., M.N., is the acting chief of the Cancer Information Service. Jeffrey Abrams, M.D., is a senior investigator in the Cancer Therapy Evaluation Program. Detra K. Robinson, M.A., is a project manager with Westat, Inc., in Rockville, Md.
Andrea M. Denicoff
All authors are affiliated with the National Cancer Institute, National Institutes of Health, in Bethesda, Md. Margo Michaels, M.P.H., is an education program specialist in the Public and Survivor Education Section, Office of Education and Special Initiatives. Andrea M. Denicoff R.N., M.S., C.A.N.P., is a clinical trials specialist in the Office of Education and Special Initiatives. Mary Anne Bright R.N., M.N., is the acting chief of the Cancer Information Service. Jeffrey Abrams, M.D., is a senior investigator in the Cancer Therapy Evaluation Program. Detra K. Robinson, M.A., is a project manager with Westat, Inc., in Rockville, Md.
Mary Anne Bright
All authors are affiliated with the National Cancer Institute, National Institutes of Health, in Bethesda, Md. Margo Michaels, M.P.H., is an education program specialist in the Public and Survivor Education Section, Office of Education and Special Initiatives. Andrea M. Denicoff R.N., M.S., C.A.N.P., is a clinical trials specialist in the Office of Education and Special Initiatives. Mary Anne Bright R.N., M.N., is the acting chief of the Cancer Information Service. Jeffrey Abrams, M.D., is a senior investigator in the Cancer Therapy Evaluation Program. Detra K. Robinson, M.A., is a project manager with Westat, Inc., in Rockville, Md.
Jeffrey Abrams
All authors are affiliated with the National Cancer Institute, National Institutes of Health, in Bethesda, Md. Margo Michaels, M.P.H., is an education program specialist in the Public and Survivor Education Section, Office of Education and Special Initiatives. Andrea M. Denicoff R.N., M.S., C.A.N.P., is a clinical trials specialist in the Office of Education and Special Initiatives. Mary Anne Bright R.N., M.N., is the acting chief of the Cancer Information Service. Jeffrey Abrams, M.D., is a senior investigator in the Cancer Therapy Evaluation Program. Detra K. Robinson, M.A., is a project manager with Westat, Inc., in Rockville, Md.
Detra K. Robinson
All authors are affiliated with the National Cancer Institute, National Institutes of Health, in Bethesda, Md. Margo Michaels, M.P.H., is an education program specialist in the Public and Survivor Education Section, Office of Education and Special Initiatives. Andrea M. Denicoff R.N., M.S., C.A.N.P., is a clinical trials specialist in the Office of Education and Special Initiatives. Mary Anne Bright R.N., M.N., is the acting chief of the Cancer Information Service. Jeffrey Abrams, M.D., is a senior investigator in the Cancer Therapy Evaluation Program. Detra K. Robinson, M.A., is a project manager with Westat, Inc., in Rockville, Md.